India, Aug. 21 -- Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company developing treatments for rare kidney diseases, recently reported second-quarter 2026 financial results and provided a business update, highlighting a strengthened cash position and upcoming clinical milestones for exaluren.
Q2 Financial Results:
The company's net loss increased to $4.5 million, or $0.39 per share, in the second quarter of 2026, compared with a net loss of $1.9 million, or $5.45 per share, in the prior-year quarter.
R&D expenses rose to $2.8 million from $0.9 million, primarily due to higher clinical trial expenses for exaluren.
G&A expenses increased to $1.6 million from $0.7 million.
Cash and cash equivalents totaled $62....